# 3-Tesla MRI Response to TACE in HCC (Liver Cancer)

> **NCT02057874** · NA · TERMINATED · sponsor: **Vanderbilt-Ingram Cancer Center** · enrollment: 2 (actual)

## Conditions studied

- Adult Primary Hepatocellular Carcinoma
- Advanced Adult Primary Liver Cancer
- Localized Resectable Adult Primary Liver Cancer
- Localized Unresectable Adult Primary Liver Cancer
- Stage A Adult Primary Liver Cancer (BCLC)
- Stage B Adult Primary Liver Cancer (BCLC)

## Interventions

- **DEVICE:** 3 Tesla Magnetic Resonance Imaging
- **DRUG:** Magnevist® (Intravenous (IV) administration of MRI contrast agent)

## Key facts

- **NCT ID:** NCT02057874
- **Lead sponsor:** Vanderbilt-Ingram Cancer Center
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2014-02
- **Primary completion:** 2015-11-19
- **Final completion:** 2015-12-04
- **Target enrollment:** 2 (ACTUAL)
- **Why stopped:** Funding unavailable
- **Last updated:** 2018-07-11

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02057874

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02057874, "3-Tesla MRI Response to TACE in HCC (Liver Cancer)". Retrieved via AI Analytics 2026-06-04 from https://api.ai-analytics.org/clinical/NCT02057874. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*